Tuesday, July 16, 2024

Lung Cancer Study Update: Genentech’s Phase II/III SKYSCRAPER-06 in Metastatic Non-Squamous NSCLC

Similar articles

Lung cancer was the focus of Genentech’s announcement regarding their Phase II/III SKYSCRAPER-06 study, which evaluated tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy against pembrolizumab and chemotherapy as a first-line treatment for untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC). The study failed to meet its primary endpoints.

The study showed reduced efficacy in progression-free survival (PFS) and overall survival (OS) for the combination of tiragolumab, Tecentriq, and chemotherapy compared to the comparator arm. The hazard ratios were 1.27 [95% CI: 1.02,1.57] for PFS and 1.33 [95% CI: 1.02, 1.73] for OS. Given these results, Genentech will unblind patients and investigators and halt the study, sharing results with health authorities and presenting findings at an upcoming medical meeting.

Lung Cancer Study Disappoints: Genentech Reflects on SKYSCRAPER-06 Outcomes and Future Directions

“These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Ongoing Phase III studies are investigating different treatment settings and indications distinct from SKYSCRAPER-06. Based on these results, relevant changes to the ongoing tiragolumab program will be evaluated.

SKYSCRAPER-06 is a global Phase II/III, randomized, placebo-controlled, double-blinded study with 542 participants. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Tiragolumab, an investigational immune checkpoint inhibitor, selectively binds to TIGIT, an inhibitory checkpoint that suppresses immune response to cancer.

Lung Cancer

Lung Cancer Treatment Insights: Tiragolumab and Tecentriq® Work Together to Amplify Immune Response

It acts as an immune amplifier with other cancer immunotherapies, like Tecentriq®, which targets the PD-L1 pathway, complementing tiragolumab’s action. Tecentriq® is a monoclonal antibody designed to bind to PD-L1 on tumor cells and immune cells, blocking interactions with PD-1 and B7.1 receptors and reactivating T cells.

Tecentriq® is indicated for treating adults with non-small cell lung cancer (NSCLC) and can be used alone or in combination with other medications based on the cancer stage and specific genetic markers. However, it has significant potential side effects, including immune system reactions that can attack normal organs and tissues. Patients should contact their healthcare provider if they develop new or worsening symptoms. Common side effects include fatigue, decreased appetite, nausea, and shortness of breath.

Genentech’s commitment to advancing cancer treatment remains strong, despite the disappointing results of the SKYSCRAPER-06 study. They continue to explore the anti-TIGIT pathway and other novel approaches in immuno-oncology. Their focus remains on leveraging scientific learnings to develop next-generation cancer therapies that can improve patient outcomes. This announcement underscores the challenges and complexities in developing effective cancer treatments and highlights the importance of continued research and innovation in the field.

 

Resource: Business Wire, July 04, 2024

You can follow our news on our Telegram and LinkedIn accounts.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article